Mirum Pharmaceuticals, Inc. (MIRM)
Price:
74.82 USD
( + 1.97 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Vertex Pharmaceuticals Incorporated
VALUE SCORE:
8
2nd position
Harmony Biosciences Holdings, Inc.
VALUE SCORE:
12
The best
Agios Pharmaceuticals, Inc.
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
NEWS
CRMD vs. MIRM: Which Specialized Biotech Stock is the Better Pick?
zacks.com
2025-09-23 11:45:20CorMedix and Mirum Pharmaceuticals are advancing niche therapies with strong launches, rising sales and strategic acquisitions shaping their growth.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
2025-09-10 18:45:00FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Mirum Pharmaceuticals: Q2 Results Continue To Show Positive Momentum
seekingalpha.com
2025-08-11 09:48:37Mirum Pharmaceuticals continues to outperform, beating revenue and earnings expectations for two consecutive quarters and raising guidance. Livmarli, Mirum's flagship drug, is driving strong revenue growth, with approvals in both the U.S. and Europe to treat symptoms of rare liver diseases. The analyst community remains unanimously bullish on the stock, and more than a half dozen analyst firms raised their price targets following Q2 results.
MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View
zacks.com
2025-08-07 12:20:13Mirum surges after second-quarter earnings and revenues top estimates, driven by Livmarli growth and a raised 2025 outlook.
Mirum Pharmaceuticals, Inc. (MIRM) Q2 2025 Earnings Call Transcript
seekingalpha.com
2025-08-06 21:09:53Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Andrew McKibben - Senior Vice President, Strategic Finance & Investor Relations Christopher Peetz - CEO & Director Eric H. Bjerkholt - Chief Financial Officer Joanne M.
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates
zacks.com
2025-08-06 18:56:15Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.52 per share a year ago.
Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
businesswire.com
2025-08-06 16:01:00FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update.
Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
zacks.com
2025-07-30 11:07:06Mirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mirum Gains 35% in 3 Months: How Should You Play the Stock?
zacks.com
2025-07-17 11:06:08MIRM jumps 35% in 3 months, driven by soaring Livmarli sales and rising demand for its bile acid products.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
2025-07-10 18:15:00FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Liver Drug Stock Rockets 236% Amid FDA Approval As Sales Accelerate; Funds Load Up
investors.com
2025-06-17 12:34:39Biotech stock Mirum Pharmaceuticals has rocketed 236% since its IPO in 2019. Shares are near a buy point after earnings.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
2025-06-10 20:40:00FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Why Is Mirum Pharmaceuticals (MIRM) Down 1.3% Since Last Earnings Report?
zacks.com
2025-06-06 12:36:43Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock?
No data to display
CRMD vs. MIRM: Which Specialized Biotech Stock is the Better Pick?
zacks.com
2025-09-23 11:45:20CorMedix and Mirum Pharmaceuticals are advancing niche therapies with strong launches, rising sales and strategic acquisitions shaping their growth.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
2025-09-10 18:45:00FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Mirum Pharmaceuticals: Q2 Results Continue To Show Positive Momentum
seekingalpha.com
2025-08-11 09:48:37Mirum Pharmaceuticals continues to outperform, beating revenue and earnings expectations for two consecutive quarters and raising guidance. Livmarli, Mirum's flagship drug, is driving strong revenue growth, with approvals in both the U.S. and Europe to treat symptoms of rare liver diseases. The analyst community remains unanimously bullish on the stock, and more than a half dozen analyst firms raised their price targets following Q2 results.
MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View
zacks.com
2025-08-07 12:20:13Mirum surges after second-quarter earnings and revenues top estimates, driven by Livmarli growth and a raised 2025 outlook.
Mirum Pharmaceuticals, Inc. (MIRM) Q2 2025 Earnings Call Transcript
seekingalpha.com
2025-08-06 21:09:53Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Andrew McKibben - Senior Vice President, Strategic Finance & Investor Relations Christopher Peetz - CEO & Director Eric H. Bjerkholt - Chief Financial Officer Joanne M.
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates
zacks.com
2025-08-06 18:56:15Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.52 per share a year ago.
Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
businesswire.com
2025-08-06 16:01:00FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update.
Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
zacks.com
2025-07-30 11:07:06Mirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mirum Gains 35% in 3 Months: How Should You Play the Stock?
zacks.com
2025-07-17 11:06:08MIRM jumps 35% in 3 months, driven by soaring Livmarli sales and rising demand for its bile acid products.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
2025-07-10 18:15:00FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Liver Drug Stock Rockets 236% Amid FDA Approval As Sales Accelerate; Funds Load Up
investors.com
2025-06-17 12:34:39Biotech stock Mirum Pharmaceuticals has rocketed 236% since its IPO in 2019. Shares are near a buy point after earnings.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
2025-06-10 20:40:00FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Why Is Mirum Pharmaceuticals (MIRM) Down 1.3% Since Last Earnings Report?
zacks.com
2025-06-06 12:36:43Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock?